IL256791B - Antibodies specific for hyperphosphorylated tua and methods of their use - Google Patents
Antibodies specific for hyperphosphorylated tua and methods of their useInfo
- Publication number
- IL256791B IL256791B IL256791A IL25679118A IL256791B IL 256791 B IL256791 B IL 256791B IL 256791 A IL256791 A IL 256791A IL 25679118 A IL25679118 A IL 25679118A IL 256791 B IL256791 B IL 256791B
- Authority
- IL
- Israel
- Prior art keywords
- tau
- antibody
- antibodies
- pathology
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512211.2A GB201512211D0 (en) | 2015-07-13 | 2015-07-13 | Agents, uses and methods |
| GBGB1518375.9A GB201518375D0 (en) | 2015-10-16 | 2015-10-16 | Agents,uses and methods |
| PCT/EP2016/066470 WO2017009308A2 (en) | 2015-07-13 | 2016-07-12 | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL256791A IL256791A (en) | 2018-03-29 |
| IL256791B true IL256791B (en) | 2022-09-01 |
Family
ID=56557664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL256791A IL256791B (en) | 2015-07-13 | 2016-07-12 | Antibodies specific for hyperphosphorylated tua and methods of their use |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10196439B2 (enExample) |
| EP (1) | EP3322442A2 (enExample) |
| JP (1) | JP6878395B2 (enExample) |
| KR (1) | KR20180030047A (enExample) |
| CN (1) | CN107847595B (enExample) |
| AU (1) | AU2016292892B2 (enExample) |
| BR (1) | BR112018000769A2 (enExample) |
| CL (1) | CL2018000096A1 (enExample) |
| CO (1) | CO2017013318A2 (enExample) |
| CR (1) | CR20180026A (enExample) |
| DO (1) | DOP2018000012A (enExample) |
| EA (1) | EA038703B1 (enExample) |
| EC (1) | ECSP18002644A (enExample) |
| GE (2) | GEP20227369B (enExample) |
| HK (1) | HK1254357A1 (enExample) |
| IL (1) | IL256791B (enExample) |
| JO (1) | JO3711B1 (enExample) |
| MA (1) | MA42446A (enExample) |
| MX (1) | MX392396B (enExample) |
| NI (1) | NI201800005A (enExample) |
| PE (1) | PE20180607A1 (enExample) |
| PH (1) | PH12018500062A1 (enExample) |
| RU (1) | RU2727911C2 (enExample) |
| SG (1) | SG10202101343RA (enExample) |
| SV (1) | SV2018005611A (enExample) |
| TN (1) | TN2017000541A1 (enExample) |
| TW (1) | TWI741987B (enExample) |
| UA (1) | UA123862C2 (enExample) |
| WO (1) | WO2017009308A2 (enExample) |
| ZA (1) | ZA201800070B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
| TN2017000543A1 (en) | 2015-07-06 | 2019-04-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| DK3452507T3 (da) | 2016-05-02 | 2022-11-14 | Prothena Biosciences Ltd | Tau-immunoterapi |
| SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| NZ748983A (en) | 2016-07-12 | 2022-12-23 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US11590304B2 (en) | 2016-08-15 | 2023-02-28 | The Board Of Regents Of The University Of Texas System | Volume control device for manually operated resuscitator and ventilation apparatus and method of use |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| EP3532064B1 (en) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| JP7217710B2 (ja) * | 2017-01-04 | 2023-02-03 | ハー・ルンドベック・アクチエゼルスカベット | 眼疾患の治療のための過リン酸化タウに特異的な抗体 |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| BR112019022906A2 (pt) | 2017-05-02 | 2020-05-26 | Prothena Biosciences Limited | Anticorpos que reconhecem tau |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| RS62551B1 (sr) | 2017-12-14 | 2021-12-31 | H Lundbeck As | Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| EP3728250A1 (en) | 2017-12-20 | 2020-10-28 | H. Lundbeck A/S | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS |
| JP2021512602A (ja) * | 2018-02-01 | 2021-05-20 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | タウに特異的に結合する結合分子 |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2020183245A2 (en) | 2019-03-11 | 2020-09-17 | Janssen Pharmaceutica Nv | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
| JP2022527087A (ja) | 2019-03-28 | 2022-05-30 | ハー・ルンドベック・アクチエゼルスカベット | タウオパチーを診断するためのｐＳ３９６アッセイの使用 |
| GB201909393D0 (en) * | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| SG10201908922UA (en) * | 2019-09-25 | 2021-04-29 | Sengenics Corp Pte Ltd | Identification of health status in the elderly using immunological biomarkers |
| EP4135841A1 (en) | 2020-04-15 | 2023-02-22 | Voyager Therapeutics, Inc. | Tau binding compounds |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| US20230265175A1 (en) | 2020-06-25 | 2023-08-24 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| CA3190987A1 (en) | 2020-08-10 | 2022-02-17 | Janssen Biotech, Inc. | Materials and methods for producing bioengineered virus specific lymphocytes |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| WO2022056192A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| KR20230084507A (ko) * | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 다중-특이적 면역 표적화 분자 및 그의 용도 |
| US20250298039A1 (en) * | 2020-11-12 | 2025-09-25 | Children`S Medical Center Corporation | Methods and compositions for tauopathy diagnosis and treatment |
| AU2021403010A1 (en) | 2020-12-16 | 2023-07-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| CN113702647B (zh) * | 2021-08-31 | 2024-03-15 | 普十生物科技(北京)有限公司 | 人生长分化因子15即时检测试剂盒、其制备方法及其应用 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023250388A1 (en) | 2022-06-22 | 2023-12-28 | Voyager Therapeutics, Inc. | Tau binding compounds |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| JP2025535871A (ja) * | 2022-09-26 | 2025-10-30 | ウォーターストーン ファーマシューティカルズ（ウーハン）カンパニー，リミティド | Ｆｃ－長鎖脂肪酸鎖を含む超長作用型プラットフォーム |
| CN116754776A (zh) * | 2023-06-20 | 2023-09-15 | 南京鼓楼医院 | 一种基于S396与S404位点的高灵敏磷酸化Tau蛋白检测方法 |
| CN116794328A (zh) * | 2023-06-20 | 2023-09-22 | 南京鼓楼医院 | 一种基于多位点的高灵敏磷酸化Tau蛋白检测方法 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025231348A1 (en) * | 2024-05-02 | 2025-11-06 | North Carolina Central University | Phospho-tau aggregation-based biomarkers for alzheimer's disease diagnosis, differentiation, and treatment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012045882A2 (en) * | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
| WO2013050567A1 (en) * | 2011-10-07 | 2013-04-11 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE172879T1 (de) | 1989-08-09 | 1998-11-15 | Rhomed Inc | Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| ATE386115T1 (de) | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| IL147765A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES TO HER2/neu |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20030162230A1 (en) * | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| EP1940442A4 (en) | 2005-08-04 | 2009-08-19 | Einstein Coll Med | Phosphorylation of tau by abl |
| AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル．エル．シー． | Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例 |
| WO2009033743A1 (en) | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| WO2010144711A2 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| AU2010312651A1 (en) | 2009-10-26 | 2012-05-03 | Otsuka Pharmaceutical Co., Ltd. | Benzazepine compound |
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| SG10201912964PA (en) * | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| EP2834270B1 (en) | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| SG10201913370PA (en) | 2012-07-03 | 2020-03-30 | Univ Washington | Antibodies to tau |
| SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| WO2014170549A1 (en) * | 2013-04-16 | 2014-10-23 | Glykos Finland Oy | A method for generating induced pluripotent stem cells |
| JP6913018B2 (ja) | 2014-07-08 | 2021-08-04 | ニューヨーク・ユニバーシティ | タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| NZ748983A (en) | 2016-07-12 | 2022-12-23 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| JP7217710B2 (ja) | 2017-01-04 | 2023-02-03 | ハー・ルンドベック・アクチエゼルスカベット | 眼疾患の治療のための過リン酸化タウに特異的な抗体 |
| US10934438B2 (en) | 2017-04-27 | 2021-03-02 | Axalta Coating Systems Ip Co., Llc | Coatings and methods for using and producing the same |
-
2016
- 2016-06-29 JO JOP/2016/0135A patent/JO3711B1/ar active
- 2016-07-04 TW TW105121106A patent/TWI741987B/zh active
- 2016-07-12 MX MX2018000505A patent/MX392396B/es unknown
- 2016-07-12 GE GEAP201614672A patent/GEP20227369B/en unknown
- 2016-07-12 CN CN201680040472.7A patent/CN107847595B/zh active Active
- 2016-07-12 TN TNP/2017/000541A patent/TN2017000541A1/en unknown
- 2016-07-12 EP EP16745421.4A patent/EP3322442A2/en active Pending
- 2016-07-12 JP JP2018501228A patent/JP6878395B2/ja active Active
- 2016-07-12 IL IL256791A patent/IL256791B/en unknown
- 2016-07-12 SG SG10202101343RA patent/SG10202101343RA/en unknown
- 2016-07-12 RU RU2018100822A patent/RU2727911C2/ru active
- 2016-07-12 CR CR20180026A patent/CR20180026A/es unknown
- 2016-07-12 AU AU2016292892A patent/AU2016292892B2/en not_active Ceased
- 2016-07-12 US US15/207,836 patent/US10196439B2/en active Active
- 2016-07-12 HK HK18113433.8A patent/HK1254357A1/zh unknown
- 2016-07-12 GE GEAP202114672A patent/GEAP202114672A/en unknown
- 2016-07-12 UA UAA201800762A patent/UA123862C2/uk unknown
- 2016-07-12 MA MA042446A patent/MA42446A/fr unknown
- 2016-07-12 BR BR112018000769-2A patent/BR112018000769A2/pt not_active Application Discontinuation
- 2016-07-12 PE PE2018000065A patent/PE20180607A1/es unknown
- 2016-07-12 WO PCT/EP2016/066470 patent/WO2017009308A2/en not_active Ceased
- 2016-07-12 EA EA201890039A patent/EA038703B1/ru unknown
- 2016-07-12 KR KR1020187001209A patent/KR20180030047A/ko active Pending
-
2017
- 2017-12-22 CO CONC2017/0013318A patent/CO2017013318A2/es unknown
-
2018
- 2018-01-04 ZA ZA2018/00070A patent/ZA201800070B/en unknown
- 2018-01-05 PH PH12018500062A patent/PH12018500062A1/en unknown
- 2018-01-11 NI NI201800005A patent/NI201800005A/es unknown
- 2018-01-11 SV SV2018005611A patent/SV2018005611A/es unknown
- 2018-01-11 DO DO2018000012A patent/DOP2018000012A/es unknown
- 2018-01-12 CL CL2018000096A patent/CL2018000096A1/es unknown
- 2018-01-12 EC ECIEPI20182644A patent/ECSP18002644A/es unknown
- 2018-11-13 US US16/188,489 patent/US10562962B2/en active Active
-
2019
- 2019-12-20 US US16/723,143 patent/US10934348B2/en active Active
-
2021
- 2021-01-08 US US17/144,355 patent/US11739140B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012045882A2 (en) * | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
| WO2013050567A1 (en) * | 2011-10-07 | 2013-04-11 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
Non-Patent Citations (1)
| Title |
|---|
| ROSSEELS, JO?LLE, ET AL., TAU MONOCLONAL ANTIBODY GENERATION BASED ON HUMANIZED YEAST MODELS: IMPACT ON TAU OLIGOMERIZATION AND DIAGNOSTICS., 31 December 2015 (2015-12-31) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256791B (en) | Antibodies specific for hyperphosphorylated tua and methods of their use | |
| Zhao et al. | A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer’s disease | |
| Chiba et al. | Amyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons | |
| AU2018200413B2 (en) | Therapeutic agent or prophylactic agent for dementia | |
| JP7029415B2 (ja) | 過リン酸化タウに特異的な抗体およびその使用方法 | |
| Angers et al. | Chronic wasting disease prions in elk antler velvet | |
| Tu et al. | Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein | |
| JP7300990B2 (ja) | タウ凝集を防止するためのモノクローナル抗α－シヌクレイン抗体 | |
| Kennedy et al. | Axon guidance by diffusible chemoattractants: a gradient of netrin protein in the developing spinal cord | |
| CN106030310B (zh) | 可溶性高分子量(hmw)tau种类及其应用 | |
| KR102471787B1 (ko) | 타우 인식 항체 | |
| Antonios et al. | Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X | |
| CN110573526B (zh) | 蜂王浆主蛋白的抗体及其用途 | |
| DE102008037564A1 (de) | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden | |
| EP2033971A1 (de) | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung | |
| CN109415434A (zh) | 识别tau的抗体 | |
| Kokubo et al. | Part of membrane-bound Aβ exists in rafts within senile plaques in Tg2576 mouse brain | |
| JP2022523516A (ja) | ヒト化抗－Ａβモノクローナル抗体及びその使用 | |
| JP2022523517A (ja) | ヒト化抗－Ａβモノクローナル抗体及びその使用 | |
| Garcia-Caballero et al. | T-type calcium channels functionally interact with spectrin (α/β) and ankyrin B | |
| WO2020156220A1 (zh) | 人源化抗Aβ单克隆抗体及其应用 | |
| Kida et al. | Adverse Effects of Aβ1-42 Oligomers: Impaired Contextual Memory and Altered Intrinsic Properties of CA1 Pyramidal Neurons | |
| Nojima et al. | Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model | |
| TWI910093B (zh) | 抗人類ｃｃｒ１單株抗體與其製造方法及其用途、產生抗人類ｃｃｒ１單株抗體之細胞、編碼抗人類ｃｃｒ１單株抗體之核酸及包含該核酸之轉形細胞、人類ｃｃｒ１之檢測或測定用試劑、人類ｃｃｒ１相關疾病之診斷及治療藥、以及抗人類ｃｃｒ１單株抗體之衍生物 | |
| WO2025047850A1 (ja) | 神経変性疾患の治療剤 |